Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$39.16 USD

39.16
2,512,037

+0.26 (0.67%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $39.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag

by Zacks Equity Research

Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.

GSK Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.

FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld

by Zacks Equity Research

AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.

Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $35.17, moving +1.35% from the previous trading session.

Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline

by Zacks Equity Research

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?

by Zacks Equity Research

Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $35.61, moving +1.19% from the previous trading session.

J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study

by Zacks Equity Research

J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.

Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab

by Zacks Equity Research

Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $34.67 in the latest trading session, marking a -0.2% move from the prior day.

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights Caterpillar, Equinor, GSK, Sysco and AmerisourceBergen

by Zacks Equity Research

Caterpillar, Equinor, GSK, Sysco and AmerisourceBergen are included in this Analyst Blog.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Sheraz Mian headshot

Top Research Reports for Caterpillar, Equinor & GSK

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Caterpillar Inc. (CAT), Equinor ASA (EQNR) and GSK plc (GSK).

GSK Signs Deal to Develop Antibodies for Treating Cancer

by Zacks Equity Research

GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $35.29 in the latest trading session, marking a +0.43% move from the prior day.

GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

by Zacks Equity Research

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.

Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance

by Zacks Equity Research

The FDA assigns a standard review to Pfizer's (PFE) BLA for pentavalent meningococcal vaccine candidate (MenABCWY), with a decision expected in October 2023.

GSK (GSK) Stock Moves -0.83%: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $34.78, marking a -0.83% move from the previous day.

3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

by Zacks Equity Research

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

Kinjel Shah headshot

3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023

by Kinjel Shah

Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.

Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals

by Zacks Equity Research

Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

by Zacks Equity Research

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.

GSK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?